NeurAxis, Inc.
AMEX:NRXSBiotechnology
Healthcare
$4.87 +4.25%
+$0.29 today
- Market cap
- $69.12M
- Beta
- 1.41
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.67
52W Low $2.20High $9.33
Volume 0.23M
Average 0.18M
Income Statement
Follow revenue through to earnings.
Revenue
$3.57M
FY 2025 · Annual
+32.9% YoYOperating Income
-$7.83M
FY 2025 · Annual
Net Income
-$7.80M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.72M | 2.68M | 2.46M | 2.69M | 3.57M |
| Cost of Revenue | 467.66K | 297.06K | 303.35K | 362K | 562.92K |
| Gross Profit | 2.25M | 2.39M | 2.16M | 2.32M | 3.01M |
| Gross Margin | 82.8% | 88.9% | 87.7% | 86.5% | 84.2% |
| Research & Development | 203.41K | 225.61K | 169.32K | 206.11K | 493.61K |
| Selling, General & Admin | 5.02M | 5.53M | 8.65M | 9.27M | 10.34M |
| Operating Expenses | 5.22M | 5.76M | 8.82M | 9.48M | 10.84M |
| Depreciation & Amortization | 36.71K | 37.13K | 40.73K | 37.83K | 59.5K |
| EBITDA | (2.95M) | (4.33M) | (9.23M) | (7.9M) | (7.67M) |
| EBITDA Margin | -108.6% | -161.1% | -375.1% | -294.2% | -214.8% |
| Operating Income | (2.97M) | (3.37M) | (6.66M) | (7.16M) | (7.83M) |
| Operating Margin | -109.1% | -125.6% | -270.9% | -266.5% | -219.4% |
| Interest Income | 0 | (2.32M) | (2.77K) | 0 | 0 |
| Interest Expense | 36.93K | 417.6K | 5.36M | 300.72K | 73.97K |
| Other Income / Expenses | (58K) | (1.41M) | (7.96M) | (1.08M) | 29.35K |
| Income Before Tax | (3.03M) | (4.78M) | (14.63M) | (8.24M) | (7.8M) |
| Pre-Tax Margin | -111.3% | -178.0% | -594.6% | -306.8% | -218.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (3.03M) | (4.78M) | (14.63M) | (8.24M) | (7.8M) |
| Net Margin | -111.3% | -178.0% | -594.6% | -306.8% | -218.5% |
| EPS (Basic) | (0.62) | (0.57) | (2.32) | (1.22) | (0.95) |
| EPS (Diluted) | (0.62) | (0.78) | (2.32) | (1.22) | (0.95) |
| 5.38M | 8.41M | 6.3M | 6.92M | 9.08M | |
| 5.38M | 8.41M | 6.3M | 6.92M | 9.08M |
NRXS Earnings Waterfall · TTM
AMEX:NRXS · Revenue to Net Income
Key Ratios
EPS$-0.80
Gross Margin84.7%
Net Margin-184.2%
P/E Ratio-6.0
P/S Ratio38.4
Analysis
$4.3M of revenue converted into -$7.3M of net income for the selected period. Gross margin is 84.7% and net margin is -184.2%, showing how much revenue survives after costs and taxes. EPS is $-0.80, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 8, 2026 |
How much revenue does NRXS generate?
NeurAxis, Inc. (NRXS) reported $3.57M of revenue in fiscal 2025.
Is NRXS profitable?
NeurAxis, Inc. (NRXS) reported -$7.80M of net income, with a net margin of -218.5%.
Continue the stock analysis
Jump to another research area for this company.